Are weight-loss pills about to become reality?
Novo Nordisk Acquires Septerna: A Strategic Move Toward Oral Obesity Medications
At a time when the fight against obesity and metabolic diseases is intensifying, Novo Nordisk has made a major move by acquiring the biotechnology company Septerna. The deal, valued at up to $2.2 billion, marks a strategic expansion of Novo Nordisk’s portfolio into innovative oral therapies, with a strong focus on drugs targeting GPCR receptors.
This decision has the potential to reshape the market for obesity and diabetes treatments, two areas where Novo Nordisk is already a global leader.
Why This Acquisition Matters
The acquisition of Septerna addresses an urgent need for innovation: most effective treatments for obesity, such as GLP-1–based therapies, are injectable. While highly effective, these treatments can pose a challenge for patients who are reluctant to use needles or have difficulty adhering to injection-based regimens.
By incorporating Septerna’s technologies, Novo Nordisk aims to develop oral therapies that maintain the efficacy of injectable drugs while offering more convenience and accessibility to a broader range of patients.
What Is Septerna and Why Is It Important?
Septerna is a California-based biotechnology company specializing in the discovery and development of drugs that act on G protein–coupled receptors (GPCRs). These receptors play a crucial role in cellular signaling and regulate key physiological functions such as appetite, insulin secretion, blood pressure, and hormonal activity.
While GPCRs are already well-established drug targets, developing small molecules that can interact with them safely and effectively has been a long-standing challenge. Septerna has developed a proprietary technology platform that enables the rapid discovery of such molecules, including those targeting previously “undruggable” GPCRs.
Novo Nordisk’s Objectives for the Acquisition
With this acquisition, Novo Nordisk aims to:
- Develop oral medications for obesity and diabetes that mimic the effects of key metabolic hormones like GLP-1, GIP, and glucagon.
- Explore new combination therapies to enhance glycemic control and promote greater weight loss.
- Expand its research into cardiometabolic diseases through GPCR-targeted molecules that influence lipid metabolism, blood pressure, and systemic inflammation.
- Reduce reliance on injections, with a clear goal of transitioning to daily oral pills with comparable effectiveness.
The Future of Oral Obesity Medications
Novo Nordisk has already found global success with injectable products like Ozempic, Wegovy, and Rybelsus—the latter being an early step toward oral delivery using semaglutide. With Septerna’s expertise, the company now plans to go further by designing entirely new small-molecule drugs that can be taken orally and act on the same or related metabolic pathways.
These new therapies could be designed to activate multiple pathways at once—suppressing appetite, increasing satiety, and improving insulin sensitivity—all in a single daily pill.
Long-Term Impact on the Pharmaceutical Industry
This move positions Novo Nordisk not only as a leader in injectable therapies but also as a frontrunner in the race to develop next-generation oral obesity treatments. As competition heats up—with companies like Eli Lilly and Pfizer also developing anti-obesity medications—innovation is the key differentiator.
If these oral therapies can match the effectiveness of injectables without compromising safety, they could transform the global obesity treatment market, which is expected to surpass $100 billion annually within the next decade.
Benefits for Patients
Patients will be the primary beneficiaries of this acquisition through:
- Easier access to effective treatments – pills are often more acceptable and practical than injections.
- Improved treatment adherence – oral medications integrate more naturally into daily routines.
- Reduced stigma – many people avoid injectable medications due to embarrassment or fear of needles.
- No injection-site side effects, improving overall treatment experience.
Part of a Broader Innovation Strategy
The Septerna acquisition is not a standalone move but part of Novo Nordisk’s broader innovation strategy. The company has been investing heavily in emerging technologies, including gene therapies, small molecules, digital health platforms, and novel drug delivery systems.
Novo Nordisk’s dual strategy appears to focus on:
- Strengthening its leadership in metabolic and endocrine diseases (obesity, diabetes, NASH).
- Diversifying its R&D capabilities through partnerships with biotech startups that offer cutting-edge technology and drug discovery expertise.
What’s Next?
Over the next few years, joint research efforts between Novo Nordisk and Septerna will focus on four initial development programs. These programs will center on small molecules targeting GLP-1, GIP, and glucagon receptors, with the aim of discovering effective and orally stable drug combinations.
If successful in preclinical and clinical phases, the resulting drugs could reach the market within 6–8 years. In an optimistic scenario, some candidates may enter human trials even sooner.
Conclusion
Novo Nordisk’s acquisition of Septerna is one of the most significant strategic developments in the biopharmaceutical industry in 2025. It signals a shift from injectable dominance to a future where oral medications for obesity and metabolic conditions become the new standard.
For Novo Nordisk, this partnership is more than just a pipeline expansion—it’s a clear statement that innovation and patient-centered accessibility will go hand in hand in addressing one of the greatest public health challenges of the 21st century.
Follow us on:
- FaceBook: Diabetes & Nutrition;
- YouTube: Diabetes Facts.